Leerink Partnrs Brokers Raise Earnings Estimates for ARWR

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Research analysts at Leerink Partnrs lifted their Q2 2025 earnings estimates for Arrowhead Pharmaceuticals in a research report issued on Tuesday, February 11th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will post earnings of ($0.32) per share for the quarter, up from their prior forecast of ($0.54). The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.40) per share. Leerink Partnrs also issued estimates for Arrowhead Pharmaceuticals’ Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.22) EPS and FY2025 earnings at ($2.14) EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97).

ARWR has been the subject of a number of other reports. Citigroup reduced their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday, November 27th. Chardan Capital restated a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday. Piper Sandler lowered their price target on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th. Sanford C. Bernstein reduced their price objective on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research note on Friday, November 29th. Finally, HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $43.33.

Arrowhead Pharmaceuticals Trading Down 1.7 %

Arrowhead Pharmaceuticals stock opened at $18.57 on Thursday. The stock has a 50-day moving average price of $20.14 and a 200 day moving average price of $21.23. The company has a market capitalization of $2.32 billion, a price-to-earnings ratio of -3.70 and a beta of 0.95. Arrowhead Pharmaceuticals has a 52 week low of $17.05 and a 52 week high of $36.72. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 2.06.

Institutional Trading of Arrowhead Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of ARWR. R Squared Ltd purchased a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at about $38,000. Values First Advisors Inc. acquired a new position in shares of Arrowhead Pharmaceuticals during the third quarter valued at approximately $52,000. Van ECK Associates Corp lifted its position in shares of Arrowhead Pharmaceuticals by 72.3% in the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 1,250 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Arrowhead Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock worth $88,000 after acquiring an additional 788 shares during the last quarter. Finally, KBC Group NV increased its position in shares of Arrowhead Pharmaceuticals by 45.9% during the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 1,644 shares in the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, CFO Kenneth Allen Myszkowski sold 27,167 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $19.83, for a total transaction of $538,721.61. Following the completion of the transaction, the chief financial officer now directly owns 473,433 shares of the company’s stock, valued at $9,388,176.39. This represents a 5.43 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Adeoye Y. Olukotun sold 2,850 shares of the stock in a transaction that occurred on Friday, December 27th. The shares were sold at an average price of $20.00, for a total value of $57,000.00. Following the transaction, the director now owns 36,740 shares in the company, valued at $734,800. This trade represents a 7.20 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 147,432 shares of company stock valued at $2,957,986 in the last ninety days. 4.30% of the stock is currently owned by corporate insiders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.